-
公开(公告)号：WO2022251224A1
公开(公告)日：2022-12-01
申请号：PCT/US2022/030739
申请日：2022-05-24
发明人： PINCHMAN, Joseph, Robert , NATALA, Srinivasa, Reddy , BUNKER, Kevin, Duane , HUANG, Peter, Qinhua
IPC分类号： A61K31/519 , A61P35/00 , C07D487/04 , C07D519/00
摘要： Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
-
公开(公告)号：WO2022082180A1
公开(公告)日：2022-04-21
申请号：PCT/US2021/071840
申请日：2021-10-13
发明人： SAMATAR, Ahmed, Abdi , DONATE, Fernando , IZADI, Hooman , PINCHMAN, Joseph, Robert , BUNKER, Kevin, Duane , HUANG, Peter, Qinhua
IPC分类号： A61K31/496 , A61K31/5355 , A61K31/7068 , A61K31/4184 , A61K31/69 , A61P35/00 , A61P35/02
摘要： The present invention relates to the combination of Bcl-2 inhibitor Compound (A) in combination with a chemotherapeutic agent Compound (B) selected from azacitidine, bendamustine, bortezomib, carfilzomib, ixazomib, busulfan, carboplatin, cytarabine, cyclophosphamide, cladribine, cisplatin, capecitabine, decitabine, etoposide, fludarabine, gemcitabine, daunorubicin, doxorubicin, ifosfamide, methotrexate and vincristine, or a pharmaceutically acceptable salt of any of the foregoing, for the treatment of a disease or condition in particular hematological cancers.
-
公开(公告)号：WO2019139899A8
公开(公告)日：2019-07-18
申请号：PCT/US2019/012695
申请日：2019-01-08
发明人： PINCHMAN, Joseph, Robert , HUANG, Peter, Qinhua , BUNKER, Kevin, Duane , SIT, Rakesh, Kumar , SAMATAR, Ahmed, Abdi
IPC分类号： C07D471/04 , C07D491/107 , C07D471/14 , C07D211/46 , C07D295/155 , A61P31/18 , A61P35/00 , A61K31/437 , A61K31/5377 , A61K31/496 , A61K31/404
摘要： Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
-
公开(公告)号：WO2022133446A1
公开(公告)日：2022-06-23
申请号：PCT/US2021/072921
申请日：2021-12-14
发明人： BUNKER, Kevin, Duane , SAMATAR, Ahmed, Abdi , DONATE, Fernando , MA, Jianhui , IZADI, Hooman , PINCHMAN, Joseph, Robert , HUANG, Peter, Qinhua
IPC分类号： A61K31/496 , A61K31/437 , A61K31/519 , A61P35/00
摘要： Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor, a SERD inhibitor, and a CDK4/6 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
-
公开(公告)号：WO2021127044A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/065409
申请日：2020-12-16
发明人： SAMATAR, Ahmed, Abdi , LI, Jiali , IZADI, Hooman , HUANG, Peter, Qinhua , BOREN, Brant, Clayton , PINCHMAN, Joseph, Robert , BUNKER, Kevin, Duane , DONATE, Fernando
IPC分类号： A61K31/496 , A61K31/5355 , A61K31/519 , A61P35/00 , A61P35/02
摘要： Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a WEE1 inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
-
公开(公告)号：WO2021007307A1
公开(公告)日：2021-01-14
申请号：PCT/US2020/041175
申请日：2020-07-08
IPC分类号： C07D401/14 , C07D417/14 , A61P35/00 , A61P35/02 , A61P35/04 , A61K31/496
摘要： Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein.
-
公开(公告)号：WO2021222114A1
公开(公告)日：2021-11-04
申请号：PCT/US2021/029181
申请日：2021-04-26
IPC分类号： C07D401/14 , C07D417/14 , A61K35/02 , A61P35/00
摘要： Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein. (I)
-
公开(公告)号：WO2021127042A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/065407
申请日：2020-12-16
发明人： SAMATAR, Ahmed, Abdi , MA, Jianhui , LI, Jiali , IZADI, Hooman , HUANG, Peter, Qinhua , HEGDE, Sayee, Gajanan , PINCHMAN, Joseph, Robert , BUNKER, Kevin, Duane , DONATE, Fernando
IPC分类号： A61K31/437 , A61K31/496 , A61P35/00
摘要： Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
-
公开(公告)号：WO2021030401A1
公开(公告)日：2021-02-18
申请号：PCT/US2020/045869
申请日：2020-08-12
发明人： UNNI, Aditya, Krishnan , PINCHMAN, Joseph, Robert , HUANG, Peter, Qinhua , BUNKER, Kevin, Duane
IPC分类号： C07C5/31 , C07C13/605
摘要： Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.
-
公开(公告)号：WO2021007303A1
公开(公告)日：2021-01-14
申请号：PCT/US2020/041168
申请日：2020-07-08
发明人： PINCHMAN, Joseph, Robert , UNNI, Aditya, Krishnan , SHAMAY, Yosef , BUNKER, Kevin, Duane , HUANG, Peter, Qinhua
IPC分类号： A61K31/495 , A61K47/42 , A61P35/00
摘要： Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.011 秒)
